More evidence needed before PCSK9 inhibitor use widens

Prohibitive costs have not dampened enthusiasm for PCSK9 inhibitors with many cardiologists calling for new lipid management guidance to include the use of the agents – and in wider patient groups. However Professor Stephen Nicholls, director and clinical council chair of the Australian Atherosclerosis Society, cautioned that more outcomes data was needed to better understand ...

Already a member?

Login to keep reading.

© 2021 the limbic